ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis

Marilynn Larkin  |  March 28, 2018

NEW YORK (Reuters Health)—After discontinuation of teriparatide, increases in bone mineral density (BMD) are greater with denosumab than with zoledronic acid, but whether that translates into a decreased fragility fracture risk remains unknown, researchers say. Teriparatide was the first anabolic treatment approved for osteoporosis in the U.S. It has been shown to increase BMD, and…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabOsteoporosisosteoporosis treatmentsteriparatide treatment for osteoporosis

PhuShutter / shutterstock.com

The FDA Approved Several New Rheumatology Drugs in 2017

Larry Beresford  |  March 18, 2018

SAN DIEGO—In a session at the 2017 ACR/ARHP Annual Meeting, Kam Nola, PharmD, MS, professor in the College of Pharmacy and vice chair in the Department of Pharmacy Practice at Lipscomb University in Nashville, Tenn., updated participants on new medications and new indications for rheumatology treatments and safety labeling changes approved by the U.S. Food…

Filed under:Drug UpdatesMeeting Reports Tagged with:abaloparatideACR/ARHP Annual MeetingAllopurinolbelimumabbrodalumabguselkumablesinuradMethotrexatesarilumabtocilizumab

3 Experts Discuss Bone Health

Thomas R. Collins  |  February 18, 2018

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting Nov. 3–8, experts discussed improving bone health in the U.S., gave tips on bone health disorders in pediatrics and reviewed new translational science findings for joint conservation in early osteonecrosis. E. Michael Lewiecki, MD, director of the New Mexico Clinical Research & Osteoporosis Center in Albuquerque, N.M., called…

Filed under:Meeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR/ARHP Annual Meetingbone and jointJuvenile arthritisOsteoarthritisOsteonecrosis

Patients with Gout May Be More Likely to Develop Osteoporosis

Scott Baltic  |  February 16, 2018

NEW YORK (Reuters Health)—People with gout face a modestly increased risk, of about 20%, for developing osteoporosis, compared to people without gout, researchers in Taiwan suggest. In their population-based study to examine a possible association between gout and subsequent osteoporosis, Dr. Victor C. Kok of Asia University (Taiwan), Taichung, and colleagues retrospectively analyzed data from…

Filed under:ConditionsGout and Crystalline ArthritisOsteoarthritis and Bone Disorders Tagged with:GoutOsteoporosisVictor C. Kok

U.S. Telehealth Industry Eyes Medicare for Its Next Big Check

Tamara Mathias  |  January 30, 2018

(Reuters)—After years of lobbying in Washington, U.S. telehealth providers have the first hints that the dam could break on public funding for an industry they say could save taxpayers billions. Four bills that could be signed into law over the next year carry the solutions to barriers that have prevented the U.S.s’ huge over-65 health…

Filed under:Technology Tagged with:appsMedicareTechnologytelehealthtelemedicine

2017 ACR/ARHP Honors & Awards, Part 2

Richard Quinn  |  January 19, 2018

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ARHP winners about their individual contributions. In addition, we profile the new class…

Filed under:Meeting ReportsProfessional Topics Tagged with:AC&RACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)Awards

Older Women Should Not Take Hormones to Prevent Chronic Diseases

Will Boggs MD  |  December 14, 2017

(Reuters Health)— Postmenopausal women should not use hormone therapy to prevent chronic medical conditions, because the risk of significant side effects outweighs the unclear evidence of a benefit, according to a government-backed panel of experts. Most chronic conditions – coronary heart disease, dementia, stroke, fractures, and breast cancer, for example – are more common with…

Filed under:Conditions Tagged with:chronic medical conditionsPostmenopausal hormone therapypostmenopausal womensignificant side effectsU.S. Preventive Services Task Force (USPSTF)

Opioid Painkiller Prescriptions May Run in Families

Lisa Rapaport  |  December 12, 2017

(Reuters Health)—When one person in a household gets prescribed opioids, the other people who live with them are more likely to get their own prescriptions for these narcotic painkillers, a U.S. study suggests. Researchers examined data on about 12.6 million people living in a household where someone was prescribed opioids and 6.4 million individuals in…

Filed under:AnalgesicsDrug Updates Tagged with:familyOpioid abuseopioid painkillersOpioids

Year in Review: Expert Covers 2017’s Key Clinical Findings

Thomas R. Collins  |  November 20, 2017

In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Filed under:Axial SpondyloarthritisConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:2017 ACR/ARHP Annual MeetingACR/ARHP Annual MeetingAnkylosing SpondylitiscardiovascularDASH dietGoutjuvenile idiopathic arthritis (JIA)Knee Osteoarthritis (OA)secukinumab

Hyperuricemia Doesn’t Always Indicate Gout in Rheumatic Disease

Veronika Sharp, MD, Alice Chuang, MD, Lily Kao, MD, RMSK, & Midori Jane Nishio, MD, RhMSUS  |  November 9, 2017

A 57-year-old Ghanaian woman was referred to our rheumatology practice with acute, left elbow swelling and pain. The referring oncologist suspected gout, because the patient had hyperuricemia. Six months before, the patient was diagnosed with stage IV human T-lymphotropic virus type 1 (HTLV-1)-associated adult T cell lymphoma (ATLL). Her initial oncologic manifestations included multiple thoracic,…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:case reportClinicalDiagnosisGouthyperuricemiamalignantoutcomepatient careRheumatic DiseaserheumatologyT cell lymphomaUltrasound

  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences